Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Receivables (2016 - 2025)

Historic Receivables for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $6.9 million.

  • Enanta Pharmaceuticals' Receivables rose 355.1% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 355.1%. This contributed to the annual value of $6.9 million for FY2025, which is 355.1% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Receivables of $6.9 million as of Q3 2025, which was up 355.1% from $8.3 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Receivables peaked at $27.6 million during Q4 2021, and registered a low of $6.6 million during Q3 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' median Receivables value was $17.8 million (recorded in 2023), while the average stood at $14.7 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Receivables soared by 1592.77% in 2021, and later tumbled by 6381.23% in 2023.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Receivables stood at $27.6 million in 2021, then fell by 18.31% to $22.6 million in 2022, then tumbled by 63.81% to $8.2 million in 2023, then dropped by 5.57% to $7.7 million in 2024, then dropped by 10.83% to $6.9 million in 2025.
  • Its Receivables stands at $6.9 million for Q3 2025, versus $8.3 million for Q2 2025 and $6.8 million for Q1 2025.